Membranous glomerulonephritis laboratory findings: Difference between revisions

	Membranous glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Membranous glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
Ultrasound
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Membranous glomerulonephritis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Membranous glomerulonephritis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Membranous glomerulonephritis laboratory findings
CDC on Membranous glomerulonephritis laboratory findings
Membranous glomerulonephritis laboratory findings in the news
Blogs on Membranous glomerulonephritis laboratory findings
Directions to Hospitals Treating Membranous glomerulonephritis
Risk calculators and risk factors for Membranous glomerulonephritis laboratory findings

VisualWikitext

Revision as of 12:58, 20 May 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Laboratory Findings

Comprehensive chemistry panel including serum albumin
Complete blood count
Urinalysis with examination of the sediment
24-hour urine collection for protein quantification and creatinine clearance
ANA and, if positive, anti-double-stranded DNA (anti-dsDNA), anti-Sm, anti-Ro/SSA, and anti-La/SSB antibodies
Tests for hepatitis B and C viruses and the human immunodeficiency virus (HIV) (see "Hepatitis B virus: Screening and diagnosis", section on 'Diagnostic algorithms' and "Diagnosis and evaluation of chronic hepatitis C virus infection", section on 'Testing algorithm' and "Screening and diagnostic testing for HIV infection", section on 'Testing algorithm')
Serum C3 and C4 complement levels
In patients older than 50 years – serum free light chains (SFLCs) and serum protein electrophoresis (SPEP) with immunofixation
Chest radiograph (or computed tomography [CT] of the chest in patients with a history of smoking or asbestos exposure)
Anti-PLA2R antibody (by enzyme-linked immunosorbent assay [ELISA])

References

Template:WH Template:WS

@@ Line 5: / Line 5: @@
 ==Overview==
-An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
-OR
-Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
-OR
-[Test] is usually normal among patients with [disease name].
-OR
-Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
-OR
-There are no diagnostic laboratory findings associated with [disease name].
 ==Laboratory Findings==
+* Comprehensive chemistry panel including serum albumin
-*There are no diagnostic laboratory findings associated with [disease name].
+* Complete blood count
-OR
+* Urinalysis with examination of the sediment
-*An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
+* 24-hour urine collection for protein quantification and creatinine clearance
-*[Test] is usually normal among patients with [disease name].
+* ANA and, if positive, anti-double-stranded DNA (anti-dsDNA), anti-Sm, anti-Ro/SSA, and anti-La/SSB antibodies
-*Laboratory findings consistent with the diagnosis of [disease name] include:
+* Tests for hepatitis B and C viruses and the human immunodeficiency virus (HIV) (see "Hepatitis B virus: Screening and diagnosis", section on 'Diagnostic algorithms' and "Diagnosis and evaluation of chronic hepatitis C virus infection", section on 'Testing algorithm' and "Screening and diagnostic testing for HIV infection", section on 'Testing algorithm')
-**[Abnormal test 1]
+* Serum C3 and C4 complement levels
-**[Abnormal test 2]
+* In patients older than 50 years – serum free light chains (SFLCs) and serum protein electrophoresis (SPEP) with immunofixation
-**[Abnormal test 3]
+* Chest radiograph (or computed tomography [CT] of the chest in patients with a history of smoking or asbestos exposure)
+* Anti-PLA2R antibody (by enzyme-linked immunosorbent assay [ELISA])
-*Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
 ==References==

Membranous glomerulonephritis laboratory findings: Difference between revisions

Revision as of 12:58, 20 May 2018

Overview

Laboratory Findings

References

Navigation menu